BECTON-DICKINSON LAUNCHING FACSCOUNT CD4 T LYMPHOCYTE COUNTER
This article was originally published in The Gray Sheet
Executive Summary
BECTON-DICKINSON LAUNCHING FACSCOUNT CD4 T LYMPHOCYTE COUNTER in the U.S. at a list price of $34,975. The company began taking orders for the device following its 510(k) clearance by FDA on Sept. 19. FACSCount, which provides absolute counts of CD4, CD8 and CD3 T lymphocytes, is intended for use in monitoring the status of HIV-positive patients; BD notes that the CD4 cells are the "cellular parameter most closely associated with HIV disease progression and therapy decisions."